Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It treats primary open-angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is employed in the management of glaucoma‑related conditions by enhancing aqueous outflow. - Primary open‑angle glaucoma: lowers intraocular pressure to slow optic nerve damage. - Ocular hypertension: reduces eye pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: helps control intraocular pressure when other causes are present.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual pigmentation change. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Paradoxical increase in intraocular pressure. - Ocular infection: signs of conjunctivitis or keratitis.

Before using Latanoprost, consider the following safety measures. - Monitor intraocular pressure regularly: ensure therapeutic effect and detect paradoxical rise. - Avoid use in active ocular inflammation: may exacerbate condition. - Do not combine with other prostaglandin analog eye drops: risk of additive side effects. - Inform ophthalmologist of any planned ocular surgery: may affect healing. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: increased risk of adverse ocular effects. - Use with systemic carbonic anhydrase inhibitors: may diminish IOP‑lowering efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction may require monitoring. - Topical NSAIDs: may increase ocular irritation. - Systemic antihistamines: possible reduction in tear production, affecting comfort.